We are pleased to announce positive topline results from our Phase 3 study in people living with #hemophilia A or B with inhibitors. Learn more:

Many people living with #IBD face delays in diagnosis often due to misattributed symptoms. In our Specialty Voices of Innovation series, Dr. Jessica Allegretti joins us to discuss the real barriers people face and how we can help close the gap. 🎥 Watch now:

Lynce Lucas transforms her cancer diagnosis into advocacy with Pfizer. Read her story in @Essence: #CancerAwareness.

At #AHSAM, we shared results from a Phase 4 trial, which is the first study exploring a gepant versus placebo for the acute treatment of migraine in adults who are unsuitable for triptans. Triptans are often the first prescription option for treating migraine. However, it’s

What does our commitment to migraine care look like? At #AHSAM, we're presenting 14 abstracts featuring data across different populations of patients with migraine, including those who:. ✔️ Are unsuitable for triptan use. ✔️ Experience multiple migraine attacks per month. ✔️ Are

We’re sharing new insights from our global Unmet Needs Survey at #EHA2025. Investigating the perspectives of people living with multiple myeloma and HCPs treating the disease to pinpoint critical gaps and barriers to optimal care. Read about our findings:

In our latest Dear Scientist episode, migraine patient & advocate Jenn sits down with Pfizer’s Chelsea Leroue, Migraine Medical Director. They explore why migraine disproportionately affects women and the urgent need for greater awareness and education. Catch the full story

At #EHA2025 we’re joining the hematology community to share data from across our growing multi-modality hematology-oncology portfolio, building on 10+ yrs of experience advancing care and strengthening our commitment to patients with blood cancer.

Knowledge is power when it comes to navigating #ProstateCancer. This #MensHealthMonth, John, Dan, and Nick share what they learned throughout their own journeys with the disease so that those navigating it anew can learn from their insights. Learn more:

.@llcoolj and Simone I. Smith faced cancer together. Now, they’ve partnered with Pfizer to encourage others to understand their risk factors and the importance of early detection. Read their story in @latimes:

📢It’s here! Pfizer’s 2024 #ImpactReport shows how we advanced science, access to care, and our commitment to responsible business growth. Because impact means more than breakthroughs—it’s about building a healthier world for all. 🔗 Read more:

Today at #ASCO25: Dr. Andrew Armstrong (@AArmstrongDuke) is sharing updates from our #ProstateCancer research program. Learn more:

One more birthday, one more moment, one more molecule – that's what the fight against cancer is all about. We're inspired to fight alongside the healthcare professionals working to give “one more” to patients. Explore our pipeline and resources at #ASCO25

With @Arvinas today at #ASCO25, and published in @NEJM, we are sharing detailed Phase 3 progression-free survival data in ESR1-mutant, ER+/HER2- advanced #BreastCancer. Read more:

A cancer breakthrough isn’t one moment. It’s decades of research, millions of data points, and resilience in the face of setbacks, all with the hope of challenging what’s possible. We’re not waiting for breakthroughs – we’re working to create them. Learn how:

Today at #ASCO25, we presented pivotal progression-free survival and overall survival results from our Phase 3 study in patients with metastatic #ColorectalCancer (mCRC) with a BRAF V600E mutation. Learn more:

At Pfizer, we have a longstanding commitment to #vaccine R&D that can help prevent infection with and the severity of certain infectious diseases. Isis brings this mindset to the lab every day, constantly working to advance scientific innovation to help public health.

At #ASCO25, we look forward to sharing late-breaking data from a Phase 3 study of a combination regimen in patients with metastatic #ColorectalCancer (mCRC) with a BRAF V600E mutation. Stay tuned for the presentation on Friday, 5/30 at 2:45pm CT.

NEW #ProstateCancer research: with Astellas Pharma, we’re sharing overall survival data in metastatic hormone-sensitive disease. Read more: #ASCO25

Drawing on his background as a physician, John made the transition into the pharmaceutical industry with a mission: to help develop innovative treatments that improve outcomes for people with cardiometabolic diseases. Learn more about his personal journey and how his team helps